The uterine sarcomas form a group of malignant tumors that arises from the smooth muscle or connective tissue of the uterus. Signs and symptoms
Clinically, uterine sarcomas and leiomyomas (fibroids) both have similar symptoms such as increased uterine size, abdominal pain and vaginal bleeding so it can be difficult to tell them apart. Unusual or postmenopausal bleeding may be a sign of uterine sarcoma and needs to be investigated. Other signs include pelvic pain, pressure, and unusual discharge. A nonpregnant uterus that enlarges quickly is suspicious. However, none of the signs are specific. Specific screening test have not been developed; a Pap smear is a screening test for cervical cancer and not designed to detect uterine sarcoma. Histology
Tumoral entities include leiomyosarcomas, endometrial stromal sarcomas, carcinosarcomas and "other" sarcomas. If the lesion originates from the stroma of the uterine lining it is an endometrial stromal sarcoma. If the uterine muscle cell is the originator the tumor is a uterine leiomyosarcoma. Carcinosarcomas comprise both malignant epithelial and malignant sarcomatous components. Diagnosis
By using T2*-weighted imaging, MRI is able to differentiate distinguishing features of leiomyomas from uterine sarcomas. Investigations by the physician include imaging (ultrasound, CAT scan, MRI) and, if possible, obtaining a tissue diagnosis by biopsy, hysteroscopy, or D&C. Ultimately the diagnosis is established by the histologic examination of the specimen. Typically malignant lesions have >10 mitosis per high power field. In contrast, a uterine leiomyoma as a benign lesion would have < 5 mitoses per high power field.
Classification
Leiomyosarcomas are now staged using the 2009 FIGO staging system (previously they were staged like endometrial carcinomas)  at the time of surgery. Stage I: tumor is limited to the uterusIA: ≤5 cm in greatest dimension
IB: >5 cmStage II: tumor extends beyond the uterus, but within the pelvisIIA: involves adnexa of uterus
IIB: involves other pelvic tissuesStage III: tumor infiltrates abdominal tissuesIIIA: 1 site
IIIB: >1 site
IIIC: regional lymph node metastasisStage IVA: invades bladder or rectum
Stage IVB: distant metastasis (including intra-abdominal or inguinal lymph nodes; excluding adnexa, pelvic and abdominal tissues)Endometrial stromal sarcomas and uterine adenosarcomas are classified as above, with the exception of different classifications for Stage I tumors. Stage I: the tumor is limited to the uterusIA: limited to endometrium/endocervix
IB: invades <½ myometrium
IC: invades ≥½ myometriumFinally, malignant mixed Müllerian tumors, a type of carcinosarcoma, are staged similarly to endometrial carcinomas. Stage I: the tumor is limited to the uterusIA: invades <½ myometrium
IB: invades ≥½ myometriumStage II: invades cervical stroma, but no extension beyond the uterus
Stage III: local and/or regional spreadIIIA: invades uterine serosa and/or adnexa
IIIB: vaginal and/or parametrial involvement
IIIC: metastases to pelvic and/or paraaortic lymph nodes
IIIC1: positive pelvic nodes
IIIC2: positive para-aortic lymph nodesStage IVA: invades bladder and/or bowel mucosa
Stage IVB: distant metastases (including intra-abdominal metastases and/or inguinal lymph nodes)

Management
Therapy is based on staging and patient condition and utilizes one or more of the following approaches. Surgery is the mainstay of therapy if feasible involving total abdominal hysterectomy with bilateral salpingo-oophorectomy. Other approaches include radiation therapy, chemotherapy, and hormonal therapy. Prognosis is relatively poor.